Merck and Eisai provide update on Phase 3 LEAP-002 trial evaluating KEYTRUDA

The safety profile of KEYTRUDA plus LENVIMA was consistent with previously reported data on the combination.

Merck updates on Phase 3 Keynote-412 trial in advanced head and neck squamous cell carcinoma

Next-gen immunotherapy drug shows promise in several advanced-stage cancers

Researchers found that the drug combination led to a sustained and tenfold increase in the production of CD8 T cells and natural killer cells

Eugia Pharma receives USFDA approval for Pemetrexed

Pemetrexed for injection is indicated for the treatment of Antineoplastics (medications used to treat cancer)

Agilent companion diagnostic expands CE-IVD Mark in Europe to include cervical cancer

Globally, cervical cancer is the fourth most common cancer among women, with approximately 30,447 new cases diagnosed in Europe in 2020

City of Hope and Imugene dose patient in Phase 1 trial to test cancer-killing oncolytic virus

City of Hope is first in world to test oncolytic virus, CF33-hNIS, in people with metastatic solid tumours

Guardant Health receives regulatory approval for Guardant360 CDx in Japan

Guardant360 CDx is a comprehensive genomic profiling test that utilizes blood samples from patients with advanced solid cancers

Molecular Health and researchers prove new approach to anticipate molecular causation

The studies demonstrate a standardized strategy to extend mechanistic modeling and systems pharmacology into drug safety and mode of action assessments that has relevance for drug development and a variety of other contexts

Novartis cancer drug trial does not meet primary end points

The company is continuing with the evaluation of canakinumab in lung cancer, and is applying findings to the overall lung cancer development plan